BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SW48 cell line is 130
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DPP4 | 3009 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0085 | 31285270 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.211 | 31285270 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.64 | 0.211 | 29693155 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | IHC staining | NA | 0.64 | 0.211 | 31810923 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and SFA | NA | 0.64 | 0.211 | 24970802 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.64 | 0.211 | 21454414 |
| EPCAM | 11529 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and FACs | NA | 0.64 | 0.211 | 25804133 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0753 | 31285270 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.64 | 0.0753 | 29307822 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by SFA and Western Blotting | NA | 0.64 | 0.0753 | 28560069 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.64 | 0.0753 | 33744851 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and RT-PCR | NA | 0.64 | 0.0753 | 28464221 |
| LGR5 | 4504 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.64 | 0.0753 | 21435460 |
| ABCB1 | 40 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0604 | 24926880 |
| ABCG2 | 74 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 24450541 |
| ABCG2 | 74 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.48 | 0.1739 | 29693155 |
| ABCG2 | 74 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.1739 | 28212529 |
| ABCG2 | 74 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.1739 | 29805588 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 24926880 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by Western Blotting | NA | 0.48 | 1 | 31139149 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by IF staining and SFA | NA | 0.48 | 1 | 31285270 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and IF staining | NA | 0.48 | 1 | 29693155 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 26785732 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | Western Blotting | NA | 0.48 | 1 | 22319203 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | IHC staining | NA | 0.48 | 1 | 31810923 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 1 | 33744851 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 32617772 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 27520449 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 31505062 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 1 | 32729895 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and SFA | NA | 0.48 | 1 | 24970802 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 1 | 21454414 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 1 | 22329848 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29805588 |
| CD44 | 1681 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and MACs | NA | 0.48 | 1 | 24696849 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 24926880 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30774996 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by SFA and Western Blotting | NA | 0.48 | 0.5461 | 28560069 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 29426374 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 31349708 |
| NANOG | 20857 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29307822 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 24926880 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30774996 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 30802541 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 35267511 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | qRT-PCR | NA | 0.48 | 0.6448 | 29426374 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 29307822 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.6448 | 21435460 |
| POU5F1 | 9221 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.6448 | 28212529 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 24926880 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and Western Blotting | NA | 0.48 | 0.7582 | 34798428 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.7582 | 22319203 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.7582 | 31139149 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.48 | 0.7582 | 29307822 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | RT-PCR followed by FACs | NA | 0.48 | 0.7582 | 29899829 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 0.7582 | 32617772 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 0.7582 | 33744851 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 34815662 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 0.7582 | 24122993 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.48 | 0.7582 | 30429213 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs and SFA | NA | 0.48 | 0.7582 | 21694723 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 21454414 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 28212529 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 29805588 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 31285270 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.7582 | 22074823 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and FACs | NA | 0.48 | 0.7582 | 25804133 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by MACs | NA | 0.48 | 0.7582 | 30941956 |
| PROM1 | 9454 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by FACs | NA | 0.48 | 0.7582 | 21720213 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 24926880 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.48 | 0.5695 | 29693155 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 30774996 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 30802541 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35267511 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | qRT-PCR | NA | 0.48 | 0.5695 | 29426374 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qPCR | NA | 0.48 | 0.5695 | 31349708 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 29307822 |
| SOX2 | 11195 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.5695 | 21435460 |
| DCLK1 | 2700 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by Western Blotting | NA | 0.4 | 0.0159 | 22319203 |
| DCLK1 | 2700 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.0159 | 26785732 |
| DCLK1 | 2700 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.0159 | 30144515 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by SFA and RT-PCR | NA | 0.32 | 0.684 | 28464221 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.32 | 0.684 | 29693155 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qPCR and ALDEFLUOR assay | NA | 0.32 | 0.684 | 31349708 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by RT-PCR and ALDEFLUOR assay | NA | 0.32 | 0.684 | 30774996 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.684 | 26785732 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.684 | 30144515 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.32 | 0.684 | 21694723 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | IHC staining | NA | 0.32 | 0.684 | 31810923 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.32 | 0.684 | 33744851 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay | NA | 0.32 | 0.684 | 19923910 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay | NA | 0.32 | 0.684 | 24122993 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 27927191 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 29805588 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 30410666 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.32 | 0.684 | 22074823 |
| ALDH1A1 | 402 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by ALDEFLUOR assay and Tumorigenicity assay | NA | 0.32 | 0.684 | 21720213 |
| MIR3120 | 38295 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and qRT-PCR | NA | 0.32 | 0.0011 | 29307822 |
| CTNNB1 | 2514 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | Western Blotting | NA | 0.28 | 0.0647 | 27517620 |
| CTNNB1 | 2514 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by SFA and Western Blotting | NA | 0.28 | 0.0647 | 28560069 |
| CTNNB1 | 2514 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by qPCR | NA | 0.28 | 0.0647 | 31349708 |
| HMGA1 | 5010 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | Western Blotting | NA | 0.28 | 0.0042 | 24833610 |
| KLF4 | 6348 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | Western Blotting | NA | 0.28 | 0.0891 | 27517620 |
| MYC | 7553 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | Western Blotting | NA | 0.28 | 0.1304 | 27517620 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | Western Blotting | NA | 0.28 | 0.6448 | 27517620 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.6448 | 30802541 |
| SCD | 10571 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0127 | 33430034 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.5695 | 30802541 |
| SOX9 | 11204 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | Western Blotting | NA | 0.28 | 0.0244 | 22319203 |
| TGFB1 | 11766 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | Western Blotting | NA | 0.28 | 0.0138 | 27517620 |
| MIR302C | 31764 | HTM/LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs for CSC marker followed by qRT-PCR | Down | 0.2 | 0.0021 | 32617772 |
| ALCAM | 400 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and RT-PCR | NA | 0.2 | 0.0583 | 28464221 |
| ALCAM | 400 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and FACs | NA | 0.2 | 0.0583 | 25804133 |
| CD24 | 1645 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Regorafenib | qRT-PCR | NA | 0.2 | 0.456 | 35197754 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Regorafenib | qRT-PCR | NA | 0.2 | 1 | 35197754 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | FACs | NA | 0.2 | 1 | 27517620 |
| DNAJB8 | 23699 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0021 | 24145190 |
| MIR127 | 31509 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.2 | 0.0042 | 33744851 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Regorafenib | qRT-PCR | NA | 0.2 | 0.7582 | 35197754 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW48 | Doxorubicin | FACs | NA | 0.2 | 0.7582 | 27517620 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.12 | 0.456 | 27520449 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.12 | 0.456 | 31505062 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 29805588 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.12 | 0.456 | 22329848 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | SFA and MACs | NA | 0.12 | 0.456 | 24696849 |
| CD24 | 1645 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs | NA | 0.12 | 0.456 | 30429213 |
| ITGA6 | 6142 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.12 | 0.0265 | 29805588 |
| ITGB1 | 6153 | LTM | Dukes Type B Colon Cancer | Adenocarcinoma | SW480 | NA | FACs followed by SFA | NA | 0.12 | 0.018 | 22329848 |